Jörg Vollmer

This inventor holds 17 USPTO granted patents and 9 published patent applications, plus 2 CIPO patents and 3 EPO patents, primarily in Immunostimulatory Oligonucleotides. Top assignees: Coley Pharmaceutical Gmbh, Coley Pharmaceutical Group, Inc., Pfizer Corporation. Active years: 2007-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jörg Vollmer. Retrieved from https://idiyas.com/inventor/jorg-vollmer

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 9)

% Patents Active = 41.2

CIPO Patents = 2

EPO Patents = 3 (Patent Applications = 5)

Average Co-Inventor Count = 3.2

ph-index = 9

Forward Citations = 391(Granted Patents)

Location History:

Düsseldorf, DE (2007 - 2012)
Dusseldorf, DE (2011 - 2013)
Duesseldorf, DE (2009 - 2014)

Company Filing History:

16 out of 27

Coley Pharmaceutical Gmbh

patents

11 out of 41

Coley Pharmaceutical Group, Inc.

University of Iowa Research Foundation

patents

5. 1 out of 4

Abalos Therapeutics Gmbh

patents

where one patent can have more than one assignee

Years Active: 2007-2026

Loading Chart...

Areas of Expertise:

Immunostimulatory Oligonucleotides

RNA Sequence Motifs

Therapeutic Virus Particles

C-Class Oligonucleotide Analogs

Nucleic Acid-Lipophilic Conjugates

Hepatitis C Treatment

CpG Nucleic Acids

Immune Modulatory Profiles

Oligoribonucleotides

Nucleic Acids

Immune Stimulatory Activity

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12708654 - NEW VIRUS PARTICLES FOR THERAPEUTIC PURPOSES (2026-08-18),

2. 8834900 - Combination motif immune stimulatory oligonucleotides with improved activity (2014-09-16),

3. 8466124 - RNA sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles (2013-06-18),

4. 8354522 - Immunostimulatory oligoribonucleotides (2013-01-15),

5. 8304396 - Immunostimulatory nucleic acids (2012-11-06),

6. 8283328 - Immunostimulatory nucleic acids (2012-10-09),

7. 8227447 - RNA sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles (2012-07-24),

8. 8198251 - Combination motif immune stimulatory oligonucleotides with improved activity (2012-06-12),

9. 8188254 - C-class oligonucleotide analogs with enhanced immunostimulatory potency (2012-05-29),

10. 8128944 - RNA sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles (2012-03-06),

11. 7998492 - Methods and products related to treatment and prevention of hepatitis C virus infection (2011-08-16),

12. 7956043 - 5' CpG nucleic acids and methods of use (2011-06-07),

13. 7795235 - Semi-soft c-class immunostimulatory oligonucleotides (2010-09-14),

14. 7662949 - Immunostimulatory oligoribonucleotides (2010-02-16),

15. 7615539 - Nucleic acid-lipophilic conjugates (2009-11-10),

Title: The Innovations of Jörg Vollmer: Advancements in Immunostimulatory Nucleic Acids

Introduction

Jörg Vollmer, an accomplished inventor based in Düsseldorf, Germany, has made significant contributions to the field of immunology. With a portfolio of 9 patents, he has dedicated his career to advancing immunostimulatory therapies that can enhance the immune response against various diseases.

Latest Patents

Among his most notable recent inventions are the immunostimulatory nucleic acids, specifically a class of soft or semi-soft CpG immunostimulatory oligonucleotides. These innovative compounds are designed to stimulate the immune system effectively, offering promising applications in therapeutic and vaccine development. The potential impact of these inventions is substantial, as they may lead to more effective treatments for diseases that require immune modulation.

Career Highlights

Jörg Vollmer has had a productive career working with prominent companies in the pharmaceutical industry. He notably worked with Coley Pharmaceutical GmbH and Coley Pharmaceutical Group, Inc., where he focused on developing advanced therapeutic modalities in immunology. His expertise and research have significantly influenced the direction of immunotherapy.

Collaborations

Throughout his career, Vollmer has collaborated with esteemed colleagues, including Arthur Mertz Krieg and Eugen Uhlmann. These partnerships have fostered innovation and have been integral to the success of his research and patented technologies.

Conclusion

Jörg Vollmer's contributions to the field of immunostimulatory nucleic acids exemplify the importance of innovation in modern medicine. His patents hold the potential to revolutionize the ways in which we approach immune response modulation, showcasing the critical role of inventors in advancing healthcare solutions. As research continues in this area, the impact of Vollmer's work may be felt for years to come.

Profile summary based on public USPTO records.